Literature DB >> 24854488

A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes.

Edgar Davidson1, Benjamin J Doranz.   

Abstract

Characterizing the binding sites of monoclonal antibodies (mAbs) on protein targets, their 'epitopes', can aid in the discovery and development of new therapeutics, diagnostics and vaccines. However, the speed of epitope mapping techniques has not kept pace with the increasingly large numbers of mAbs being isolated. Obtaining detailed epitope maps for functionally relevant antibodies can be challenging, particularly for conformational epitopes on structurally complex proteins. To enable rapid epitope mapping, we developed a high-throughput strategy, shotgun mutagenesis, that enables the identification of both linear and conformational epitopes in a fraction of the time required by conventional approaches. Shotgun mutagenesis epitope mapping is based on large-scale mutagenesis and rapid cellular testing of natively folded proteins. Hundreds of mutant plasmids are individually cloned, arrayed in 384-well microplates, expressed within human cells, and tested for mAb reactivity. Residues are identified as a component of a mAb epitope if their mutation (e.g. to alanine) does not support candidate mAb binding but does support that of other conformational mAbs or allows full protein function. Shotgun mutagenesis is particularly suited for studying structurally complex proteins because targets are expressed in their native form directly within human cells. Shotgun mutagenesis has been used to delineate hundreds of epitopes on a variety of proteins, including G protein-coupled receptor and viral envelope proteins. The epitopes mapped on dengue virus prM/E represent one of the largest collections of epitope information for any viral protein, and results are being used to design better vaccines and drugs.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  G protein-coupled receptor; envelope; epitope; high-throughput; mapping; shotgun mutagenesis

Mesh:

Substances:

Year:  2014        PMID: 24854488      PMCID: PMC4137951          DOI: 10.1111/imm.12323

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  44 in total

1.  Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.

Authors:  Germaine Fuh; Ping Wu; Wei-Ching Liang; Mark Ultsch; Chingwei V Lee; Barbara Moffat; Christian Wiesmann
Journal:  J Biol Chem       Date:  2005-12-22       Impact factor: 5.157

Review 2.  Mapping the epitopes of antibodies.

Authors:  Robert C Ladner
Journal:  Biotechnol Genet Eng Rev       Date:  2007

3.  Computational characterization of B-cell epitopes.

Authors:  Nimrod D Rubinstein; Itay Mayrose; Dan Halperin; Daniel Yekutieli; Jonathan M Gershoni; Tal Pupko
Journal:  Mol Immunol       Date:  2007-11-26       Impact factor: 4.407

4.  Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.

Authors:  Shee-Mei Lok; Victor Kostyuchenko; Grant E Nybakken; Heather A Holdaway; Anthony J Battisti; Soila Sukupolvi-Petty; Dagmar Sedlak; Daved H Fremont; Paul R Chipman; John T Roehrig; Michael S Diamond; Richard J Kuhn; Michael G Rossmann
Journal:  Nat Struct Mol Biol       Date:  2008-02-10       Impact factor: 15.369

5.  Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.

Authors:  William B Messer; Ruklanthi de Alwis; Boyd L Yount; Scott R Royal; Jeremy P Huynh; Scott A Smith; James E Crowe; Benjamin J Doranz; Kristen M Kahle; Jennifer M Pfaff; Laura J White; Carlos A Sariol; Aravinda M de Silva; Ralph S Baric
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-02       Impact factor: 11.205

6.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

7.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

8.  Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Whitney E Purtha; Theodore Oliphant; Grant E Nybakken; Jacob J Schlesinger; John T Roehrig; Gregory D Gromowski; Alan D Barrett; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

9.  Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.

Authors:  Tiffani A Greene; Suzanne Alarcon; Anu Thomas; Eli Berdougo; Benjamin J Doranz; Paul A S Breslin; Joseph B Rucker
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

10.  Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.

Authors:  Melissa A Edeling; S Kyle Austin; Bimmi Shrestha; Kimberly A Dowd; Swati Mukherjee; Christopher A Nelson; Syd Johnson; Manu N Mabila; Elizabeth A Christian; Joseph Rucker; Theodore C Pierson; Michael S Diamond; Daved H Fremont
Journal:  PLoS Pathog       Date:  2014-04-17       Impact factor: 6.823

View more
  74 in total

1.  Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.

Authors:  Edgar Davidson; Christopher Bryan; Rachel H Fong; Trevor Barnes; Jennifer M Pfaff; Manu Mabila; Joseph B Rucker; Benjamin J Doranz
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

2.  Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.

Authors:  Philipp A Ilinykh; Kai Huang; Rodrigo I Santos; Pavlo Gilchuk; Bronwyn M Gunn; Marcus M Karim; Jenny Liang; Mallorie E Fouch; Edgar Davidson; Diptiben V Parekh; James B Kimble; Colette A Pietzsch; Michelle Meyer; Natalia A Kuzmina; Larry Zeitlin; Erica Ollmann Saphire; Galit Alter; James E Crowe; Alexander Bukreyev
Journal:  Cell Host Microbe       Date:  2020-04-21       Impact factor: 21.023

Review 3.  High throughput functional epitope mapping: revisiting phage display platform to scan target antigen surface.

Authors:  Gertrudis Rojas; Yaima Tundidor; Yanelys Cabrera Infante
Journal:  MAbs       Date:  2014       Impact factor: 5.857

4.  Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles.

Authors:  David F Tucker; Jonathan T Sullivan; Kimberly-Anne Mattia; Christine R Fisher; Trevor Barnes; Manu N Mabila; Rona Wilf; Chidananda Sulli; Meghan Pitts; Riley J Payne; Moniquetta Hall; Duncan Huston-Paterson; Xiaoxiang Deng; Edgar Davidson; Sharon H Willis; Benjamin J Doranz; Ross Chambers; Joseph B Rucker
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-16       Impact factor: 11.205

5.  Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.

Authors:  Jarrod J Mousa; Marion F Sauer; Alexander M Sevy; Jessica A Finn; John T Bates; Gabriela Alvarado; Hannah G King; Leah B Loerinc; Rachel H Fong; Benjamin J Doranz; Bruno E Correia; Oleksandr Kalyuzhniy; Xiaolin Wen; Theodore S Jardetzky; William R Schief; Melanie D Ohi; Jens Meiler; James E Crowe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

6.  High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers.

Authors:  Jonathan T Sullivan; Chidananda Sulli; Alberto Nilo; Anila Yasmeen; Gabriel Ozorowski; Rogier W Sanders; Andrew B Ward; P J Klasse; John P Moore; Benjamin J Doranz
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

7.  Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice.

Authors:  Gopal Sapparapu; Estefania Fernandez; Nurgun Kose; Julie M Fox; Robin G Bombardi; Haiyan Zhao; Christopher A Nelson; Aubrey L Bryan; Trevor Barnes; Edgar Davidson; Indira U Mysorekar; Daved H Fremont; Benjamin J Doranz; Michael S Diamond; James E Crowe
Journal:  Nature       Date:  2016-11-07       Impact factor: 49.962

8.  Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.

Authors:  Rachel H Fong; Soma S R Banik; Kimberly Mattia; Trevor Barnes; David Tucker; Nathan Liss; Kai Lu; Suganya Selvarajah; Surabhi Srinivasan; Manu Mabila; Adam Miller; Marcus O Muench; Alain Michault; Joseph B Rucker; Cheryl Paes; Graham Simmons; Kristen M Kahle; Benjamin J Doranz
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

9.  Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope.

Authors:  Feng Long; Michael Doyle; Estefania Fernandez; Andrew S Miller; Thomas Klose; Madhumati Sevvana; Aubrey Bryan; Edgar Davidson; Benjamin J Doranz; Richard J Kuhn; Michael S Diamond; James E Crowe; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-14       Impact factor: 11.205

Review 10.  HCV E2 core structures and mAbs: something is still missing.

Authors:  Matteo Castelli; Nicola Clementi; Giuseppe A Sautto; Jennifer Pfaff; Kristen M Kahle; Trevor Barnes; Benjamin J Doranz; Matteo Dal Peraro; Massimo Clementi; Roberto Burioni; Nicasio Mancini
Journal:  Drug Discov Today       Date:  2014-08-27       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.